Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Lab Invest. 2010 Mar 15;90(5):665–673. doi: 10.1038/labinvest.2010.51

Table 2.

Immunohistochemical profile of primary IPMNs

Case Invasion Subtype1 Cytokeratin2 MUC12 MUC22 p16 TP532 DPC4/SMAD4
1 yes/MI3 PB/ONC exp exp no exp lost4 no exp intact
2 yes PB exp exp no exp lost exp intact
3 yes PB exp exp5 no exp lost no exp intact6
4 yes GAST/PB exp exp7 no exp intact no exp intact
5 yes INT exp no exp exp intact no exp intact
6 no GAST/INT exp no exp exp intact no exp intact
7 no GAST/INT exp no exp exp7 intact no exp intact
8 no GAST/PB exp exp7 no exp intact no exp intact
9 no INT exp no exp exp intact no exp intact
10 no INT exp no exp exp intact no exp intact
11 no GAST exp no exp no exp intact no exp intact
12 no INT exp no exp exp intact no exp intact
13 no GAST exp no exp no exp intact no exp intact
14 no GAST exp no exp no exp intact no exp intact
1

ONC, Oncocytic; PB, Pancreatobiliary; GAST, Gastric; INT, Intestinal.

2

no exp = no expression, exp= expression.

3

MI = Microscopic < 1mm invasion

4

Focally lost

5

Non invasive IPMN was negative, while invasive adenocarcinoma was positive.

6

Non invasive IPMN was intact, while lost in invasive adenocarcinoma.

7

Focally positive expression